Dr Satyen Gohil specialises in treating patients with CLL and Lymphoma and leads a number of clinical trials for these conditions. He is also a key member of the HLH (Haemophagnocytic Lymphohistiocytosis) multidisciplinary team (MDT) that provides advice at the national HLH MDT. He also runs the UCLH Histiocytosis clinic, seeing patients with rare histiocytic disorders such as Langerhans cell histiocytosis and Erdheim Chester disease. He is a member of the NCRI CLL and Lymphoma Science groups.
Dr Gohil undertook a PhD developing novel immune therapies for cancer at UCLH before spending two years at the Dana Farber Cancer Institute in Boston, USA undertaking translational research into the tumour microenvironment, clonal evolution and response and resistance to CAR-T cell therapy in lymphoproliferative disorders.
A list of research publications can be found at: https://www.ncbi.nlm.nih.gov/myncbi/1Xar9BovcgJA1/bibliography/public/